• About
    • Company Profile
    • Company Introduction
    • R&D
      • Core Technology
      • PTS: Functional Mechanism
      • R&D Center
      • Paper Publish
    • History
    • Our Team
    • Partnership
      • Partnerships – Human Indication
      • Partnerships – Animal Drugs
  • News
    • Coming event
    • News Focus
    • Activites section
    • Announcement
  • Products
    • Para-Toluenesulfonamide (PTS)
      • PTS: Functional Mechanism
      • Product Features
      • Comparison with existing cancer treatments
    • Market Position
    • R&D
      • PTS100
      • PTS500
      • PTS02
      • GWA103
      • GWA106
  • Clinical Trials
    • Product progress
    • Compassionate use
      • Compassionate use cases
  • Partnership
    • Partnerships – Human Indication
    • Partnerships – Animal Drugs
  • Animals
  • Medical
    • Cosmetics
      • MAGIC SKIN GEL
        • DM
    • ROAN
      • DM
    • Pet Gel-Speedling
  • Investors
    • Important news
      • 2026/9/24 To announce in accordance with the provisions of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies
      • 2026/9/19 On behalf of Tianjin Chase Sun Jiandakang, PTS Phase II HCC trial abstract in China accepted for presentation at ESMO Asia 2026.
      • 2026/9/10 On behalf of subsidiary Tianjin Chase Sun Jiandakang, PTS-302 NDA was accepted for review in Morocco.
      • 2026/09/05 Gongwin Pet Biopharm: Pet anti-cancer drug Gwa103 passes MOA technical review for NDA.
      • 2026/8/25 In accordance with the provisions of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies
      • 2026/8/25 Company's Board of Directors has approved the consolidated financial report for the Second quarter of year 2026
    • Financial area
      • Annual Report
      • Monthly Revenue
        • 2026
        • 2025
        • 2024
      • Consolidated Financial Reports
    • Shareholders area
    • Corporate Governance
  • Contact

下載產品DM

  • LINKEDIN
  • YOUTUBE
  • 中文
  • EN

INQUIRY

()
  • 中文
  • EN

下載產品DM

SCROLL DOWN

  • Home
  • News
News
  • Coming event
    • HUMAN
    • PETS
  • News Focus
    • Gongwin-KY Invited by EIEV in the UAE to Explore PTS Applications in Equine Oncology
    • Breakthrough in Pet Cancer Treatment: Gongwin's Novel Canine Melanoma Drug Clears Key Regulatory Milestone
    • Gongwin-KY's Liver Cancer Therapy Published in International Journal; Phase III Clinical Trial Planned
    • New Anti-Cancer Weapon Secures U.S. Patent as Gongwin Eyes Global Licensing
  • Activites section
    • Emirates International Endurance Village(EIEV) in Abu Dhabi, UAE
    • TSIR 2026 with Veterinarians
    • 2026 13th Veterinary Conference of the Chinese Veterinary Medical Association
    • 20206 APSCVIR
  • Announcement
    • PTS Injection for Recurrent Hepatocellular Carcinoma Adjacent to the Heart: A Case Report
    • Clinical outcomes of PTS treatment in equine melanoma
    • Ablative therapy for equine cutaneous tumors
    • WEVA 2026 Thailand article
    • ASCO-Publication article
    • Gongwin Biopharm Expands an new PTS Ablation Approach for Lung Cancer Across Southeast Asia

News

Coming event

Coming event

News Focus

News Focus

Activites section

Activites section

Welcome to Gongwin BioPharm’s Events section. We actively participate in leading global pharmaceutical and medical conferences and industry events, where we share our latest R&D advances, foster international collaboration, and reaffirm our commitment to advancing innovative solutions for cancer treatment.

 

Announcement

Announcement

Announcement about Gongwin Biopharm Co., Ltd.'s news update.

 

TOP

Please enter a product name
  • LINKEDIN
  • YOUTUBE
Gongwin Biopharm Co., Ltd.
TEL +886-2-2503-5282
MAIL info@gongwinbiopharm.com
ADDRESS 3F, No. 80, Sec. 1, Jianguo N. Rd., Zhongshan Dist., Taipei City 10491, Taiwan
  • LINKEDIN
  • YOUTUBE
© 2026 Gongwin Biopharm Co., Ltd. All rights reserved. Designed By  Winho
Privacy policy  |  Sitemap